These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21391003)

  • 21. Assessing missing data assumptions in longitudinal studies: an example using a smoking cessation trial.
    Yang X; Shoptaw S
    Drug Alcohol Depend; 2005 Mar; 77(3):213-25. PubMed ID: 15734221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat.
    Matilde Sanchez M; Chen X
    Stat Med; 2006 Apr; 25(7):1169-81. PubMed ID: 16397861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
    Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
    Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statistical considerations for vaccine immunogenicity trials. Part 1: Introduction and bioassay design and analysis.
    Plikaytis BD; Carlone GM
    Vaccine; 2005 Feb; 23(13):1596-605. PubMed ID: 15694512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity analysis of intention-to-treat estimates when withdrawals are related to unobserved compliance status.
    Salim A; Mackinnon A; Griffiths K
    Stat Med; 2008 Apr; 27(8):1164-79. PubMed ID: 17724782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
    Dallow NS; Leonov SL; Roger JH
    Pharm Stat; 2008; 7(1):53-68. PubMed ID: 17390306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The statistician's role in the prevention of missing data.
    Hughes S; Harris J; Flack N; Cuffe RL
    Pharm Stat; 2012; 11(5):410-6. PubMed ID: 22807372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian analysis of hierarchical pattern-mixture models for clinical trials data with attrition and comparisons to commonly used ad-hoc and model-based approaches.
    Demirtas H
    J Biopharm Stat; 2005; 15(3):383-402. PubMed ID: 15920887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compliance in clinical trials: impact on design, analysis and interpretation.
    Pledger GW
    Epilepsy Res Suppl; 1988; 1():125-33. PubMed ID: 3072187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical evaluation of HIV vaccines in early clinical trials.
    Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
    Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of vaccines - bridging from stability data to continuous safety and efficacy throughout shelf life - an always reliable approach?
    Pfleiderer M
    Biologicals; 2009 Nov; 37(6):364-8. PubMed ID: 19773184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of a binary composite endpoint with missing data in components.
    Quan H; Zhang D; Zhang J; Devlamynck L
    Stat Med; 2007 Nov; 26(26):4703-18. PubMed ID: 17431851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of incomplete longitudinal binary data using multiple imputation.
    Li X; Mehrotra DV; Barnard J
    Stat Med; 2006 Jun; 25(12):2107-24. PubMed ID: 16220495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
    Siddiqui O; Hung HM; O'Neill R
    J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Missing data mechanisms in a dose-finding adaptive trial.
    Liu K; Entsuah R
    J Biopharm Stat; 2012; 22(2):329-37. PubMed ID: 22251177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analyzing incomplete longitudinal clinical trial data.
    Molenberghs G; Thijs H; Jansen I; Beunckens C; Kenward MG; Mallinckrodt C; Carroll RJ
    Biostatistics; 2004 Jul; 5(3):445-64. PubMed ID: 15208205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Handling of missing data in long-term clinical trials: a case study.
    Janssens M; Molenberghs G; Kerstens R
    Pharm Stat; 2012; 11(6):442-8. PubMed ID: 22888095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials.
    Jones AP; Riley RD; Williamson PR; Whitehead A
    Clin Trials; 2009 Feb; 6(1):16-27. PubMed ID: 19254930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.